U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Recurrent Malignant Glioma

MedGen UID:
1646561
•Concept ID:
C4684861
•
Neoplastic Process
Synonyms: Recurrent High Grade Glioma; Recurrent High-Grade Glioma

Definition

The reemergence of malignant glioma after a period of remission. [from NCI]

Professional guidelines

PubMed

Early clinical trials of Toca 511 and Toca FC show a promising novel treatment for recurrent malignant glioma.
Philbrick BD, Adamson DC
Expert Opin Investig Drugs 2019 Mar;28(3):207-216. doi: 10.1080/13543784.2019.1572112. PMID: 30676111
Management of recurrent malignant glioma--neurosurgical strategies.
Kostron H, Bauer R
Wien Med Wochenschr 2011 Jan;161(1-2):20-1. doi: 10.1007/s10354-010-0861-7. PMID: 21312095
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.
Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ
Lancet Oncol 2008 May;9(5):453-61. doi: 10.1016/S1470-2045(08)70125-6. PMID: 18452856

Recent clinical studies

Etiology

Safety and effectiveness of bevacizumab in Japanese patients with malignant glioma: a post-marketing surveillance study.
Motoo N, Hayashi Y, Shimizu A, Ura M, Nishikawa R
Jpn J Clin Oncol 2019 Dec 18;49(11):1016-1023. doi: 10.1093/jjco/hyz125. PMID: 31665343Free PMC Article
Efficacy and Safety of Hypofractionated Stereotactic Radiotherapy for Recurrent Malignant Gliomas: A Systematic Review and Meta-analysis.
Hu YJ, Chen D, Zhang LF, Chen J
World Neurosurg 2019 Jul;127:176-185. Epub 2019 Apr 6 doi: 10.1016/j.wneu.2019.03.297. PMID: 30959254
Patterns of re-irradiation for recurrent gliomas and validation of a prognostic score.
Post CCB, Kramer MCA, Smid EJ, van der Weide HL, Kleynen CE, Heesters MAAM, Verhoeff JJC
Radiother Oncol 2019 Jan;130:156-163. Epub 2018 Nov 13 doi: 10.1016/j.radonc.2018.10.034. PMID: 30446315
Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma.
Lang FF, Conrad C, Gomez-Manzano C, Yung WKA, Sawaya R, Weinberg JS, Prabhu SS, Rao G, Fuller GN, Aldape KD, Gumin J, Vence LM, Wistuba I, Rodriguez-Canales J, Villalobos PA, Dirven CMF, Tejada S, Valle RD, Alonso MM, Ewald B, Peterkin JJ, Tufaro F, Fueyo J
J Clin Oncol 2018 May 10;36(14):1419-1427. Epub 2018 Feb 12 doi: 10.1200/JCO.2017.75.8219. PMID: 29432077Free PMC Article
Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma.
Ruden E, Reardon DA, Coan AD, Herndon JE 2nd, Hornsby WE, West M, Fels DR, Desjardins A, Vredenburgh JJ, Waner E, Friedman AH, Friedman HS, Peters KB, Jones LW
J Clin Oncol 2011 Jul 20;29(21):2918-23. Epub 2011 Jun 20 doi: 10.1200/JCO.2011.34.9852. PMID: 21690470Free PMC Article

Diagnosis

Boron neutron capture therapy and add-on bevacizumab in patients with recurrent malignant glioma.
Furuse M, Kawabata S, Wanibuchi M, Shiba H, Takeuchi K, Kondo N, Tanaka H, Sakurai Y, Suzuki M, Ono K, Miyatake SI
Jpn J Clin Oncol 2022 May 5;52(5):433-440. doi: 10.1093/jjco/hyac004. PMID: 35079791
Safety and effectiveness of bevacizumab in Japanese patients with malignant glioma: a post-marketing surveillance study.
Motoo N, Hayashi Y, Shimizu A, Ura M, Nishikawa R
Jpn J Clin Oncol 2019 Dec 18;49(11):1016-1023. doi: 10.1093/jjco/hyz125. PMID: 31665343Free PMC Article
Early clinical trials of Toca 511 and Toca FC show a promising novel treatment for recurrent malignant glioma.
Philbrick BD, Adamson DC
Expert Opin Investig Drugs 2019 Mar;28(3):207-216. doi: 10.1080/13543784.2019.1572112. PMID: 30676111
Primetime for antiangiogenic therapy.
Tabatabai G, Stupp R
Curr Opin Neurol 2009 Dec;22(6):639-44. doi: 10.1097/WCO.0b013e328332ba28. PMID: 19786873
Novel anti-angiogenic therapies for malignant gliomas.
Norden AD, Drappatz J, Wen PY
Lancet Neurol 2008 Dec;7(12):1152-60. doi: 10.1016/S1474-4422(08)70260-6. PMID: 19007739

Therapy

Boron neutron capture therapy and add-on bevacizumab in patients with recurrent malignant glioma.
Furuse M, Kawabata S, Wanibuchi M, Shiba H, Takeuchi K, Kondo N, Tanaka H, Sakurai Y, Suzuki M, Ono K, Miyatake SI
Jpn J Clin Oncol 2022 May 5;52(5):433-440. doi: 10.1093/jjco/hyac004. PMID: 35079791
Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma.
Lang FF, Conrad C, Gomez-Manzano C, Yung WKA, Sawaya R, Weinberg JS, Prabhu SS, Rao G, Fuller GN, Aldape KD, Gumin J, Vence LM, Wistuba I, Rodriguez-Canales J, Villalobos PA, Dirven CMF, Tejada S, Valle RD, Alonso MM, Ewald B, Peterkin JJ, Tufaro F, Fueyo J
J Clin Oncol 2018 May 10;36(14):1419-1427. Epub 2018 Feb 12 doi: 10.1200/JCO.2017.75.8219. PMID: 29432077Free PMC Article
Therapeutic options for recurrent malignant glioma.
Niyazi M, Siefert A, Schwarz SB, Ganswindt U, Kreth FW, Tonn JC, Belka C
Radiother Oncol 2011 Jan;98(1):1-14. Epub 2010 Dec 13 doi: 10.1016/j.radonc.2010.11.006. PMID: 21159396
Primetime for antiangiogenic therapy.
Tabatabai G, Stupp R
Curr Opin Neurol 2009 Dec;22(6):639-44. doi: 10.1097/WCO.0b013e328332ba28. PMID: 19786873
Antiangiogenic therapy in malignant glioma: promise and challenge.
Sathornsumetee S, Rich JN
Curr Pharm Des 2007;13(35):3545-58. doi: 10.2174/138161207782794130. PMID: 18220791

Prognosis

Early clinical trials of Toca 511 and Toca FC show a promising novel treatment for recurrent malignant glioma.
Philbrick BD, Adamson DC
Expert Opin Investig Drugs 2019 Mar;28(3):207-216. doi: 10.1080/13543784.2019.1572112. PMID: 30676111
Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma.
Lang FF, Conrad C, Gomez-Manzano C, Yung WKA, Sawaya R, Weinberg JS, Prabhu SS, Rao G, Fuller GN, Aldape KD, Gumin J, Vence LM, Wistuba I, Rodriguez-Canales J, Villalobos PA, Dirven CMF, Tejada S, Valle RD, Alonso MM, Ewald B, Peterkin JJ, Tufaro F, Fueyo J
J Clin Oncol 2018 May 10;36(14):1419-1427. Epub 2018 Feb 12 doi: 10.1200/JCO.2017.75.8219. PMID: 29432077Free PMC Article
Management of recurrent malignant glioma--neurosurgical strategies.
Kostron H, Bauer R
Wien Med Wochenschr 2011 Jan;161(1-2):20-1. doi: 10.1007/s10354-010-0861-7. PMID: 21312095
Novel anti-angiogenic therapies for malignant gliomas.
Norden AD, Drappatz J, Wen PY
Lancet Neurol 2008 Dec;7(12):1152-60. doi: 10.1016/S1474-4422(08)70260-6. PMID: 19007739
Antiangiogenic therapy in malignant glioma: promise and challenge.
Sathornsumetee S, Rich JN
Curr Pharm Des 2007;13(35):3545-58. doi: 10.2174/138161207782794130. PMID: 18220791

Clinical prediction guides

Safety and effectiveness of bevacizumab in Japanese patients with malignant glioma: a post-marketing surveillance study.
Motoo N, Hayashi Y, Shimizu A, Ura M, Nishikawa R
Jpn J Clin Oncol 2019 Dec 18;49(11):1016-1023. doi: 10.1093/jjco/hyz125. PMID: 31665343Free PMC Article
Efficacy and Safety of Hypofractionated Stereotactic Radiotherapy for Recurrent Malignant Gliomas: A Systematic Review and Meta-analysis.
Hu YJ, Chen D, Zhang LF, Chen J
World Neurosurg 2019 Jul;127:176-185. Epub 2019 Apr 6 doi: 10.1016/j.wneu.2019.03.297. PMID: 30959254
Early clinical trials of Toca 511 and Toca FC show a promising novel treatment for recurrent malignant glioma.
Philbrick BD, Adamson DC
Expert Opin Investig Drugs 2019 Mar;28(3):207-216. doi: 10.1080/13543784.2019.1572112. PMID: 30676111
Primetime for antiangiogenic therapy.
Tabatabai G, Stupp R
Curr Opin Neurol 2009 Dec;22(6):639-44. doi: 10.1097/WCO.0b013e328332ba28. PMID: 19786873
Antiangiogenic therapy in malignant glioma: promise and challenge.
Sathornsumetee S, Rich JN
Curr Pharm Des 2007;13(35):3545-58. doi: 10.2174/138161207782794130. PMID: 18220791

Recent systematic reviews

Radiological Recurrence Patterns after Bevacizumab Treatment of Recurrent High-Grade Glioma: A Systematic Review and Meta-Analysis.
Cho SJ, Kim HS, Suh CH, Park JE
Korean J Radiol 2020 Jul;21(7):908-918. doi: 10.3348/kjr.2019.0898. PMID: 32524791Free PMC Article
Hypofractionated stereotactic radiotherapy combined with chemotherapy or not in the management of recurrent malignant gliomas: A systematic review and meta-analysis.
Hu YJ, Zhang LF, Ding C, Chen D, Chen J
Clin Neurol Neurosurg 2019 Aug;183:105401. Epub 2019 Jun 25 doi: 10.1016/j.clineuro.2019.105401. PMID: 31260910
Perfusion MRI as the predictive/prognostic and pharmacodynamic biomarkers in recurrent malignant glioma treated with bevacizumab: a systematic review and a time-to-event meta-analysis.
Choi SH, Jung SC, Kim KW, Lee JY, Choi Y, Park SH, Kim HS
J Neurooncol 2016 Jun;128(2):185-94. Epub 2016 Apr 23 doi: 10.1007/s11060-016-2102-4. PMID: 27108275
Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis.
Xu T, Chen J, Lu Y, Wolff JE
BMC Cancer 2010 Jun 2;10:252. doi: 10.1186/1471-2407-10-252. PMID: 20525214Free PMC Article
A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma.
Dinnes J, Cave C, Huang S, Milne R
Br J Cancer 2002 Feb 12;86(4):501-5. doi: 10.1038/sj.bjc.6600135. PMID: 11870527Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...